deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01096615

Effect Of Probiotic Lactobacillus Paracasei Lp-33 For The Management Of Rhinitis In People Sensitized To Allergens (BionAtlanta)

Evaluation of the Effect of Probiotic Lactobacillus Paracasei Lp-33 for the Management of Rhinitis in People Sensitized to Allergens. A Double Blind Randomized Parallel Placebo Controlled Study. (GA2LEN STUDY) BIONATLANTA Project

Sponsor: Merck Medication Familiale

Conditions Rhinitis
Updated 9 times since 2017 Last updated: Jul 25, 2012 Started: Apr 30, 2010 Primary completion: Sep 30, 2011 Completion: Sep 30, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Rhinitis, this trial is completed. The trial is conducted by Merck Medication Familiale and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshotCompleted~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshotCompleted~Mar 2026 – present · 4 months · monthly snapshotCompleted

Change History

9 versions recorded
  1. Mar 2026 — Present [monthly]

    Completed PHASE3

  2. Feb 2026 — Mar 2026 [monthly]

    Completed PHASE3

  3. Sep 2025 — Feb 2026 [monthly]

    Completed PHASE3

  4. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

Show 4 earlier versions
  1. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Medication Familiale
  • Novonesis
Data source: Merck Medication Familiale

For direct contact, visit the study record on ClinicalTrials.gov .